Neurocrine Biosciences (NASDAQ:NBIX) Downgraded by StockNews.com
StockNews.com lowered shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) from a strong-buy rating to a buy rating in a research note released on Friday morning. Several other research analysts also recently issued reports on NBIX. Piper Sandler upped their price target on shares of Neurocrine Biosciences from $95.00 to $100.00 and gave the stock […]
More Stories
Acting Attorney General Blanche Rejects Speculation About Bondi’s Departure
By Jack Phillips Interim Attorney General Todd Blanche dismissed speculation that Pam Bondi left her position as attorney general in...
US Fighter Jet Downed Over Iran, One Crew Member Rescued, Search Ongoing
By Tom Ozimek Search-and-rescue efforts were underway in southern Iran on April 3 after an American fighter jet was shot...
Trump Signals Possible US Operation to Reopen Strait of Hormuz
By Tom Ozimek U.S. President Donald Trump said on April 3 that the United States could “easily” reopen the Strait...
Age of Attraction Season 2? Renewal, Couples, Release Date, and Trailer
After a positive review of the debut of season 1 on March 11, 2026, people are craving more for the...
‘Bob’s Burgers’ Actor Identified as Driver Rescued From Fiery New Hampshire Crash
By Haika Mrema Actor and comedian Eugene Mirman has been identified as the driver rescued from a burning vehicle following...
Trump Says Pam Bondi Is out as His Attorney General
By Matthew Vadum President Donald Trump said on April 2 that Pam Bondi will no longer be the U.S. attorney...